Home » Topics » Conferences

Conferences
RSS

Potential antiparkinsonian agent emerges from series of subtype-selective NMDA receptor antagonists

Sep. 2, 1999

Novel antifungal agents targeting fungal prolyl-tRNA synthetase

Sep. 2, 1999

More ACS news: preclinical profile of a novel protein farnesyltransferase inhibitor, Sch-207758

Sep. 2, 1999

Inhibitors of MMPs based on D-penicillamine presented by Agouron at ACS meeting

Sep. 2, 1999

Glaxo Wellcome selects anti-HCMV compound GW-275175X for further study

Sep. 2, 1999

Research at St. Charles Pharmaceuticals discussed at ACS

Sep. 2, 1999

CombiChem presents design and synthesis of selective D4 ligands at ACS meeting

Sep. 2, 1999

Antrin photoangioplasty safe and clinically active in PAD therapy

Sep. 2, 1999

ACS news: new compounds from Merck & Co. potently and selectively inhibit 5alpha-reductase type 1

Sep. 1, 1999

p38 inhibitor RPR-200765A designated candidate for development in arthritis Rx

Sep. 1, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...
IMV-101 shows promise for B-cell malignancies
BioWorld Science
IMV-101 is a new CAR T-cell therapy targeting CD19 developed by Suzhou Immunofoco Biotechnology Co. Ltd. for the potential treatment of B-cell malignancies and...